Opinion|Videos|September 13, 2024
Similarities and Differences among Bispecifics: BCMA vs non-BCMA
Medical experts examine differences and similarities in the referral process and treatment protocols for non–BCMA-targeted vs BCMA-targeted bispecific therapies, including aspects like step-up dosing and premedication.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Is the process different/similar for patients who might be receiving non–BCMA-targeted bispecific vs BCMA-targeted bispecific?
Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step-up dosing, premedication/prophylaxis, etc.
Advertisement
Related to this article
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
3
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5